Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Arteriosclerosis and Thrombosis A Journal of Vascular Biology

• Publication date

  1994-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/01.ATV.14.3.438PMID 8123649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells.

  1993cited by this paper
• Disruption of microtubules inhibits the stimulation of tissue plasminogen activator expression and promotes plasminogen activator inhibitor type 1 expression in human endothelial cells.

  1992cited by this paper
• Fibrinolytic parameters and lipoprotein (a) levels in plasma of patients with coronary artery disease.

  1991cited by this paper
• Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells.

  1991cited by this paper
• Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population.

  1991cited by this paper
• Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.

  1991cited by this paper
• High Density Lipoprotein Inhibits Low Density Lipoprotein Binding and Uptake by Bovine Aortic Endothelial Cells

  1990cited by this paper
• Lipoprotein(a), fibrin binding, and plasminogen activation.

  1990cited by this paper
• Lp(a): An Interloper into the Fibrinolytic System?

  1990cited by this paper
• Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator.

  1990cited by this paper
• A potential basis for the thrombotic risks associated with lipoprotein(a)

  1989cited by this paper
• Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis

  1989cited by this paper
• Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen.

  1989cited by this paper
• Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA.

  1989cited by this paper
• Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin.

  1989cited by this paper
• Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin.

  1989cited by this paper
• Lipoprotein(a): A Genetically Determined Lipoprotein Containing a Glycoprotein of the Plasminogen Family

  1988cited by this paper
• The cell-binding domains of plasminogen and their function in plasma.

  1988cited by this paper
• Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells.

  1988cited by this paper
• Lipoprotein Lp(a): A Risk Factor for Myocardial Infarction

  1988cited by this paper
• Lipoprotein (a) and plasminogen are immunochemically related.

  1988cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen.

  1987cited by this paper
• cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

  1987cited by this paper
• Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1.

  1986cited by this paper
• The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

  1986cited by this paper
• Lp(a) lipoprotein as a risk factor for myocardial infarction.

  1986cited by this paper
• A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis.

  1985cited by this paper
• Immunochemical heterogeneity of human plasma high density lipoproteins. Identification with apolipoprotein A-I- and A-II-specific monoclonal antibodies.

  1985cited by this paper
• Mechanism of the association of HDL3 with endothelial cells, smooth muscle cells, and fibroblasts. Evidence against the role of specific ligand and receptor proteins.

  1984cited by this paper
• Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells.

  1984cited by this paper
• Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.

  1983cited by this paper
• A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

  1978cited by this paper
• Interaction between high density and low density lipoproteins uptake and degradation by cultured human fibroblasts.

  1977cited by this paper

• Lipoprotein (a) as a risk factor for prosthetic heart valve thrombosis

  2025cites this paper
• Pulmonary haemorrhage and extensive arterial thrombosis with anabolic steroid abuse

  2023cites this paper
• Tale of Two Systems: the intertwining duality of fibrinolysis and lipoprotein metabolism.

  2023cites this paper
• Lipoprotein (A) In Type 2 Diabetes Mellitus as A Marker of Atherosclerotic Cardiovascular Disease

  2022cites this paper
• Incidence and Hematological Biomarkers Associated With Preoperative Deep Venous Thrombosis Following Foot Fractures

  2020cites this paper
• A SHORT STUDY ON THE CLINICO PATHOLOGICAL CORRELATION OF SERUM HOMOCYSTEINE LEVEL

  2020cites this paper
• Lipoprotein(a) in clinical practice: New perspectives from basic and translational science

  2018cites this paper
• Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm

  2017cites this paper
• Fibrinogen as a Biomarker in Vascular Disease and its Prognostic Impact During Venous and Arterial Thrombolysis

  2015cites this paper
• Fibrinogen and catheter-directed thrombolysis.

  2014cites this paper
• Lipid parameters and venous thromboembolism: clinical evidence, pathophysiology and therapeutic implications

  2012cites this paper
• Interaction between homocysteine and lipoprotein(a) increases the prevalence of coronary artery disease/myocardial infarction in women: a case-control study.

  2012cites this paper
• Lipoprotein(a): Cellular Effects and Molecular Mechanisms

  2012cites this paper
• Role of homocysteine and lipoprotein (A) in atherosclerosis: An update

  2011cites this paper
• ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS (rs3798220) IN THE LPA GENE REGION WITH SERUM Lp(a) LEVELS IN A MIXED POPULATION

  2011cites this paper
• Lipoprotein (a) and Stroke: An Overview

  2010cites this paper
• Influencia de la concentración de la lipoproteína(a) en la consecución de objetivos terapéuticos de colesterol LDL en pacientes de alto riesgo cardiovascular. Importancia del colesterol LDL corregido

  2010cites this paper
• Lipoprotein a: where are we now?

  2009cites this paper
• Beyond the established risk factors of myocardial infarction : lifestyle factors and novel biomarkers

  2009cites this paper
• Novel markers of peripheral arterial disease

  2009cites this paper
• Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

  2008cites this paper
• Genetic background determines response to hemostasis and thrombosis

  2006influential citation
• Cell biology and lipoproteins in atherosclerosis.

  2006cites this paper
• Cyclooxygenase expression in human diabetes

  2006cites this paper
• Lipids and atherosclerosis

  2006cites this paper
• Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells

  2004cites this paper
• Genetic and Plasma Markers of Venous Thromboembolism in Patients with High Grade Glioma

  2004cites this paper
• Interrelationships between the fibrinolytic system and lipoproteins in the pathogenesis of coronary atherosclerosis.

  2004cites this paper
• Correlation between the extent of coronary atherosclerosis and lipid profile

  2004cites this paper
• Reconstituted High-Density Lipoprotein Inhibits Thrombin-Induced Endothelial Tissue Factor Expression Through Inhibition of RhoA and Stimulation of Phosphatidylinositol 3-Kinase but not Akt/Endothelial Nitric Oxide Synthase

  2004cites this paper
• Lipoprotein(a): biology and clinical importance.

  2004cites this paper
• Lipoproteína(a) y aterotrombosis

  2003cites this paper
• Does lipoprotein(a) inhibit elastolysis in abdominal aortic aneurysms?

  2003cites this paper
• Emerging Risk Factors for Atherosclerotic Vascular Disease

  2003cites this paper
• Lipoprotein(a): An Emerging Cardiovascular Risk Factor

  2003cites this paper
• ATVB in Focus Lipoproteins, Inflammation, and Atherosclerosis

  2003cites this paper
• Correlation between the extent of coronary atherosclerosis and lipid profile.

  2003cites this paper
• The role of immune and inflammatory processes in the development of macrovascular disease in diabetes.

  2003cites this paper
• Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells.

  2003cites this paper
• Rupture of the atherosclerotic plaque : does a good animal model exist ?

  2003cites this paper
• Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells Published, JLR Papers in Press, May 1, 2003. DOI 10.1194/jlr.M200281-JLR200

  2003cites this paper
• Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence.

  2003cites this paper
• Endothelial Protection by High-Density Lipoproteins: From Bench to Bedside

  2003cites this paper
• Cross-over study on effects of Mediterranean diet in two randomly selected population samples

  2003cites this paper
• Dyslipoproteinemia and Fibrinolysis

  2003cites this paper
• HDL and arteriosclerosis: beyond reverse cholesterol transport.

  2002cites this paper
• Fibrinolysis Defect in Long-Term Hemodialysis Patients with Type 2 Diabetes mellitus and Its Relation to Metabolic Disorders

  2002cites this paper
• Cholesterol lowering and the vessel wall: new insights and future perspectives.

  2001cites this paper
• Stimulation of Interleukin-8 Production in Human THP-1 Macrophages by Apolipoprotein(a)

  2001cites this paper
• Inhibition of Fibrinolysis by Lipoprotein(a)

  2001cites this paper
• Comparison of the effects of O2*-/HO* free radical- and copper ions-oxidized LDL or lipoprotein(a) on the endothelial cell releases of tissue plasminogen activator and plasminogen activator inhibitor-1.

  2001cites this paper
• Lipoprotein(a): from ancestral benefit to modern pathogen?

  2000cites this paper
• Fibrinolytic Proteins and Progression of Coronary Artery Disease in Relation to Gemfibrozil Therapy

  2000cites this paper
• Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice.

  2000cites this paper
• Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells.

  2000cites this paper
• Pathophysiological Basis of the Acute Coronary Syndromes

  2000cites this paper
• Tissue Plasminogen Activator: Biological and Physiological Relevance for Vascular Surgeons

  2000cites this paper
• Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells.

  2000cites this paper
• Lipoprotein effects on the vessel wall.

  2000cites this paper
• Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells.

  2000cites this paper
• High-density lipoprotein: multipotent effects on cells of the vasculature.

  1999cites this paper
• Low-density lipoprotein activates Jun N-terminal kinase (JNK) in human endothelial cells.

  1999cites this paper
• Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study.

  1999cites this paper
• [Acute coronary syndromes: physiopathology and therapeutic aspects].

  1999cites this paper
• Thrombogenic Risk Factors for Cardiovascular Disease in Dialysis Patients

  1999cites this paper
• Elevated levels of lipoprotein (a) in patients suffering from myocardial infarction with carotid atherosclerotic lesions.

  1999cites this paper
• Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus.

  1999cites this paper
• Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells.

  1998cites this paper
• Acute coronary syndromes: recent achievements and future aspects

  1998cites this paper
• Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).

  1998cites this paper
• Effects of lipids and lipoproteins on thrombosis and rheology.

  1998cites this paper
• Lipoprotein(a) as a risk factor for coronary artery disease.

  1998cites this paper
• Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL.

  1998cites this paper
• Tissue plasminogen activator-biologic perspective for surgeons.

  1997cites this paper
• Effect of lipids on glomerular fibrinolysis in vitro.

  1997cites this paper
• Lipoprotein(a): structural implications for pathophysiology

  1997cites this paper
• Hemostasis disorders in chronic renal failure.

  1997cites this paper
• Studies on effects of Lp(a) lipoprotein on gene expression in endothelial cells in vitro

  1997cites this paper
• Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells.

  1997cites this paper
• Acute coronary syndromes and their pathophysiological basis

  1997cites this paper
• Significance of glomerular deposition of apolipoprotein (a) in various glomerulopathies.

  1997cites this paper
• Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process.

  1997cites this paper
• Peripheral arterial thrombosis in two young men using anabolic steroids.

  1997cites this paper
• Diminished Fibrinolysis in Diabetes Mellitus and its Implication for Diabetic Vascular Disease

  1997cites this paper
• Hypertriglyceridemic VLDL decreases plasminogen binding to endothelial cells and surface-localized fibrinolysis.

  1996cites this paper
• Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease.

  1996cites this paper
• Modification of lipoproteins in diabetes.

  1996cites this paper
• Modified lipoproteins, cytokines and macrovascular disease in non-insulin-dependent diabetes mellitus.

  1996cites this paper
• Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus.

  1996cites this paper
• [Biology of the endothelial cell and atherogenesis].

  1995cites this paper
• 5 Fibrinolysis and atherosclerosis

  1995cites this paper
• Hypofibrinolysis and increased lipoprotein (a) coincide in stroke.

  1995cites this paper
• Peripheral Blood Monocyte Synthesis of Plasminogen Activator Inhibitor 2 in Response to Native and Modified LDL

  1995cites this paper
• Postmenopausal hormone-replacement therapy and cardiovascular risk.

  1995cites this paper
• Fibrinolysis and atherosclerosis.

  1995cites this paper
• Interactions amongst insulin, lipoproteins and haemostatic function relevant to coronary heart disease.

  1994cites this paper
• Fibrinolysis and atherosclerosis: An update

  1994cites this paper